HHS Secretary Robert F. Kennedy Jr. confirmed with ongoing financial interests in vaccine litigation, earning $856,559 in referral fees while controlling federal health policy. Despite resignation from consulting arrangements, he retains potential profit from Merck vaccine litigation, raising …
robert-f-kennedy-jrchildrens-health-defenseHHSNIHMerck+4 morerfk-jranti-vaccinehhsconflict-of-interestbiotech-investments+5 more
The Senate confirmed former Finance Committee Chairman Max Baucus (D-MT) as U.S. Ambassador to China by a vote of 96-0, ending his 36-year congressional career. Baucus had served as chairman and ranking member of the powerful Senate Finance Committee, where he was the chief architect of the …
Max BaucusSenate Finance CommitteeMerckUnitedHealth GroupJeffrey Forbesrevolving-doorlobbyingcongressional-corruptionhealthcareregulatory-capture
Dr. Julie Gerberding, who served as CDC Director from 2002-2009, joined Merck as president of the company’s vaccine division shortly after leaving government service. This move sparked significant controversy because during her tenure at the CDC, Gerberding oversaw the agency’s …
Dr. Julie GerberdingCDCMerckGardasil vaccineregulatory-capturecdcpharmaceuticalsrevolving-doorvaccines+1 more
FDA epidemiologist Dr. David Graham delivered explosive testimony before the U.S. Senate Finance Committee, declaring that ’the FDA, as currently configured, is incapable of protecting America against another Vioxx. We are virtually defenseless.’ Graham revealed that his study showed …
Dr. David GrahamFDAMerckU.S. Senate Finance CommitteeGovernment Accountability Projectregulatory-capturefdapharmaceuticalswhistleblowervioxx+2 more
Merck voluntarily withdraws Vioxx (rofecoxib) from the market after concealing evidence that the blockbuster arthritis drug increases heart attack and stroke risk. Internal company documents reveal that Merck knew of cardiovascular dangers years before withdrawal, while the FDA failed to act on …
MerckFood and Drug Administration (FDA)David GrahamRaymond Gilmartinhealthcarepharmaceutical-industryregulatory-capturefdadrug-safety+1 more